Brief: Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
30/01/2024 12:20
Jan 30 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS ANNOUNCES NEW PUBLICATION
REINFORCING THE
CLINICAL POTENTIAL OF ITS CCL24-NEUTRALIZING ANTIBODY CM-101 IN
PRIMARY SCLEROSING CHOLANGITIS
* CHEMOMAB THERAPEUTICS LTD - CM-101 PHASE 2 PSC TRIAL HAS
COMPLETED PATIENT ENROLLMENT WITH TOPLINE DATA READOUT TARGETED
FOR MIDYEAR 2024
Source text for Eikon: ID:nPn5tZV4ja
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update